Alnylam Pharma (ALNY) Tops Q1 EPS by 92c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $227.12 +1.42%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($0.01), $0.92 better than the analyst estimate of ($0.93). Revenue for the quarter came in at $594.19 million versus the consensus estimate of $588.75 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
- LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
